From: Doxorubicin PK/PD modeling in multiple myeloma: towards in silico trials
Parameter | Unit | Estimate | SD | CV % |
---|---|---|---|---|
\(k_p\) | 1/h | 0.0198 | 0.002 | 10.3 |
\(\theta \) | dimensionless | 262209 | 13686 | 5.2 |
\(K_{dmax}\) | 1/h | 0.0435 | 0.0025 | 5.7 |
\(X_{BHS}\) | nM | 47.5 | 9.83 | 20.7 |
\(\gamma \) | 1/h | 0.0044 | 0.0004 | 10.3 |
\(N_0\) (ctrl) | dimensionless | 10370 | 2043 | 19.7 |
\(N_0\) (10nM) | dimensionless | 12080 | 1140 | 9.4 |
\(N_0\) (20nM) | dimensionless | 19586 | 1224 | 6.2 |
\(N_0\) (40nM) | dimensionless | 5596 | 530 | 9.4 |
\(N_0\) (50nM) | dimensionless | 5411 | 274 | 5.1 |
\(N_0\) (200nM) | dimensionless | 8101 | 611 | 7.5 |
\(N_0\) (450nM) | dimensionless | 3785 | 151 | 4.0 |
\(N_0\) (900nM) | dimensionless | 3394 | 575 | 16.9 |